The status and future trends of sotoraxib (AMG 510) in targeted therapy of lung cancer

Sotorasib (Sotorasib, AMG 510) is an oral KRAS G12C inhibitor specifically targeted against KRAS carriers Patients with G12Cmutated non-small cell lung cancer (NSCLC). KRASMutation is one of the common types of driver gene mutations in lung cancer. In the past, there was a lack of effective targeted drugs. Sotoracib specifically and irreversibly binds to the KRAS G12C protein and keeps it in an inactive state, thereby inhibiting downstream signaling pathways and blocking tumor cell proliferation.

The emergence of sotoracib has filled the gap in targeted therapy for KRAS G12C mutations and has become an important option for precision treatment of non-small cell lung cancer. Clinical studies have shown that monotherapy can significantly shrink tumors and improve symptoms in about 30%-40% of patients. Compared with traditional chemotherapy, sotoracib is better tolerated and is convenient for oral administration. It is especially suitable for patients with advanced NSCLC who have failed previous chemotherapy or immunotherapy.

The future development direction of sotoraxib mainly includes combination therapy and drug resistance management. Researchers are exploring its use in combination with immune checkpoint inhibitors, MEK inhibitors or other targeted drugs to improve response rates and extend progression-free survival. At the same time, research on resistance mechanisms is also advancing, such as KRAS secondary mutations or activation of downstream signaling pathways, which provides a basis for the development of second-generation or combination strategies.

With the popularization of molecular testing, more lung cancer patients can know their KRAS G12C status and achieve precise treatment. Sotoracib not only plays a role in advanced NSCLC, but may also be expanded into combination therapy, adjuvant therapy or early intervention. Its good oral properties and specific targeting mechanism make it important in the future treatment of lung cancer, and is expected to become one of the important standard therapies for patients with KRAS mutated lung cancer.

Reference link:https://www.drugs.com